These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36414855)

  • 1. Significance of cardiovascular comorbidity in patients with chronic myelomonocytic leukemia.
    Lackner D; Geissler K
    Wien Med Wochenschr; 2023 Feb; 173(1-2):27-33. PubMed ID: 36414855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of hypergammaglobulinemia in patients with chronic myelomonocytic leukemia.
    Zack MT; Geissler K
    Wien Med Wochenschr; 2023 Feb; 173(1-2):21-26. PubMed ID: 36445600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of reduced renal function in patients with chronic myelomonocytic leukemia.
    Heschl J; Geissler K
    Wien Med Wochenschr; 2023 Feb; 173(1-2):3-8. PubMed ID: 36282402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant.
    Ricci C; Fermo E; Corti S; Molteni M; Faricciotti A; Cortelezzi A; Lambertenghi Deliliers G; Beran M; Onida F
    Clin Cancer Res; 2010 Apr; 16(8):2246-56. PubMed ID: 20371679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features.
    Palomo L; Garcia O; Arnan M; Xicoy B; Fuster F; Cabezón M; Coll R; Ademà V; Grau J; Jiménez MJ; Pomares H; Marcé S; Mallo M; Millá F; Alonso E; Sureda A; Gallardo D; Feliu E; Ribera JM; Solé F; Zamora L
    Oncotarget; 2016 Aug; 7(35):57021-57035. PubMed ID: 27486981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukaemia.
    Machherndl-Spandl S; Jäger E; Barna A; Gurbisz M; Marschon R; Graf T; Graf E; Geissler C; Hoermann G; Nösslinger T; Pfeilstöcker M; Bettelheim P; Zach O; Weltermann A; Heibl S; Thaler J; Zebisch A; Sill H; Stauder R; Webersinke G; Kusec R; Ulsperger E; Schneeweiss B; Öhler L; Germing U; Valent P; Tüchler H; Geissler K
    Eur J Haematol; 2021 Aug; 107(2):265-274. PubMed ID: 33998054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poor Prognostic Implication of ASXL1 Mutations in Korean Patients With Chronic Myelomonocytic Leukemia.
    Kim HY; Lee KO; Park S; Jang JH; Jung CW; Kim SH; Kim HJ
    Ann Lab Med; 2018 Nov; 38(6):495-502. PubMed ID: 30027691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population-based study.
    Moreno Berggren D; Kjellander M; Backlund E; Engvall M; Garelius H; Lorenz F; Nilsson L; Rasmussen B; Lehmann S; Hellström-Lindberg E; Jädersten M; Ungerstedt J; Ejerblad E
    Br J Haematol; 2021 Feb; 192(3):474-483. PubMed ID: 32501529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic myelomonocytic leukemia: myeloproliferative variant.
    Onida F; Beran M
    Curr Hematol Rep; 2004 May; 3(3):218-26. PubMed ID: 15087071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age-related mutations and chronic myelomonocytic leukemia.
    Mason CC; Khorashad JS; Tantravahi SK; Kelley TW; Zabriskie MS; Yan D; Pomicter AD; Reynolds KR; Eiring AM; Kronenberg Z; Sherman RL; Tyner JW; Dalley BK; Dao KH; Yandell M; Druker BJ; Gotlib J; O'Hare T; Deininger MW
    Leukemia; 2016 Apr; 30(4):906-13. PubMed ID: 26648538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of CSF3R, SRSF2 and SETBP1 mutations in chronic neutrophilic leukemia and chronic myelomonocytic leukemia.
    Ouyang Y; Qiao C; Chen Y; Zhang SJ
    Oncotarget; 2017 Mar; 8(13):20834-20841. PubMed ID: 28209919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myelomonocytic skewing in chronic myelomonocytic leukemia: phenotypic, molecular and biologic features and impact on survival.
    Geissler K; Jäger E; Barna A; Graf T; Graf E; Öhler L; Hoermann G; Valent P
    Eur J Haematol; 2021 May; 106(5):627-633. PubMed ID: 33432601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of abnormal blood coagulation in patients with chronic myelomonocytic leukemia.
    Weinfurtner C; Geissler K
    Wien Med Wochenschr; 2023 Feb; 173(1-2):9-14. PubMed ID: 36205826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased cardiovascular comorbidities in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia presenting with systemic inflammatory and autoimmune manifestations.
    Kipfer B; Daikeler T; Kuchen S; Hallal M; Andina N; Allam R; Bonadies N
    Semin Hematol; 2018 Oct; 55(4):242-247. PubMed ID: 30502853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic value of the interaction between ASXL1 and TET2 gene mutations in patients with chronic myelomonocytic leukemia: a meta-analysis.
    Zhao W; Zhang C; Li Y; Li Y; Liu Y; Sun X; Liu M; Shao R
    Hematology; 2022 Dec; 27(1):367-378. PubMed ID: 35306971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RAS mutations are rare events in Philadelphia chromosome-negative/bcr gene rearrangement-negative chronic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemia.
    Hirsch-Ginsberg C; LeMaistre AC; Kantarjian H; Talpaz M; Cork A; Freireich EJ; Trujillo JM; Lee MS; Stass SA
    Blood; 1990 Sep; 76(6):1214-9. PubMed ID: 2205309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of SETBP1 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia, and chronic neutrophilic leukemia: A meta-analysis.
    Shou LH; Cao D; Dong XH; Fang Q; Wu Y; Zhang Y; Fei JP; Xu BL
    PLoS One; 2017; 12(2):e0171608. PubMed ID: 28158286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic Myelomonocytic Leukemia With Fibrosis Is a Distinct Disease Subset With Myeloproliferative Features and Frequent JAK2 p.V617F Mutations.
    Gur HD; Loghavi S; Garcia-Manero G; Routbort M; Kanagal-Shamanna R; Quesada A; Khogeer H; Pierce S; Medeiros LJ; Kantarjian H; Khoury JD
    Am J Surg Pathol; 2018 Jun; 42(6):799-806. PubMed ID: 29596070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of ASXL1 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: A meta-analysis.
    Lin Y; Zheng Y; Wang ZC; Wang SY
    Hematology; 2016 Sep; 21(8):454-61. PubMed ID: 27077763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of RAS-Pathway Mutations and Spontaneous Myeloid Colony Growth with Progression and Transformation in Chronic Myelomonocytic Leukemia-A Retrospective Analysis in 337 Patients.
    Geissler K; Jäger E; Barna A; Gurbisz M; Graf T; Graf E; Nösslinger T; Pfeilstöcker M; Tüchler H; Sliwa T; Keil F; Geissler C; Heibl S; Thaler J; Machherndl-Spandl S; Zach O; Weltermann A; Bettelheim P; Stauder R; Zebisch A; Sill H; Schwarzinger I; Schneeweiss B; Öhler L; Ulsperger E; Kusec R; Germing U; Sperr WR; Knöbl P; Jäger U; Hörmann G; Valent P
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32344757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.